Alexion Buys A Complementary Business With Achillion
The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.
You may also be interested in...
Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.
While the drug appears more efficacious than Alexion’s C5 inhibitors, those drugs could prove difficult to dethrone given how entrenched they are in PNH therapy.
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.